Related Experiment Videos
Antisense sequence-directed cross-linking of DNA oligonucleotides by mitomycin C
1Department of Chemistry, Hunter College, City University of New York, New York 10021, USA.
Bioconjugate Chemistry
|September 1, 1996
Summary
Novel anticancer drug conjugates, mitomycin C (MC) linked to oligodeoxyribonucleotides (ODNs), show promise for gene expression inhibition. These MC-ODN conjugates specifically alkylate DNA targets, suggesting potential therapeutic applications.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Anticancer Drug Development
Background:
- Mitomycin C (MC) is a clinically used anticancer drug that alkylates DNA.
- MC preferentially targets 5'-d(CG) sequences in duplex DNA via bioreduction.
- Oligodeoxyribonucleotides (ODNs) can be functionalized for targeted drug delivery.
Purpose of the Study:
- To synthesize and investigate the interaction of MC-ODN conjugates with complementary DNA targets.
- To explore the potential of MC-ODN conjugates as specific inhibitors of gene expression.
Main Methods:
- Synthesis of MC-ODN conjugates with varying tether lengths (n=6, 12).
- Enzymatic bioreductive activation of MC-ODN conjugates.
- Incubation with 32P-radiolabeled complementary DNA targets.
- Analysis of products using polyacrylamide gel electrophoresis and phosphorimaging.
Main Results:
- MC-ODN conjugates formed slow-moving radiolabeled products with complementary DNA targets (15-25% yield).
- Product formation was dependent on complementary duplex formation.
- Evidence suggests DNA target alkylation occurs at the guanine 2-amino group by the MC moiety.
Conclusions:
- MC-ODN conjugates can specifically alkylate DNA targets upon duplex formation.
- These conjugates represent a novel approach for delivering reductively activated drugs.
- MC-ODN conjugates hold potential as specific inhibitors of cellular or viral gene expression.